Korro Bio (NASDAQ:KRRO) Issues Quarterly Earnings Results

Korro Bio (NASDAQ:KRRO) released its quarterly earnings data on Tuesday. The company reported ($2.43) EPS for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.04), Yahoo Finance reports.

Korro Bio Stock Performance

Shares of NASDAQ KRRO traded up $2.66 during mid-day trading on Wednesday, reaching $39.02. 44,312 shares of the company traded hands, compared to its average volume of 50,112. Korro Bio has a fifty-two week low of $9.15 and a fifty-two week high of $97.91. The company’s fifty day moving average is $41.30 and its two-hundred day moving average is $53.21.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on KRRO shares. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Korro Bio in a research report on Wednesday. Royal Bank of Canada lowered their target price on Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research note on Wednesday. William Blair initiated coverage on Korro Bio in a research report on Wednesday. They issued an “outperform” rating and a $180.00 target price for the company. Finally, BMO Capital Markets reissued an “outperform” rating and set a $120.00 price target on shares of Korro Bio in a report on Wednesday, May 15th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Korro Bio presently has an average rating of “Buy” and an average price target of $135.00.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).